Comprehensive M&A data with integrated detailed company information

Zur Rose to pick up Apotal’s division
Posted on Friday, 26 June 2020 13:56
The Swiss Zur Rose Group has signed off on a deal to buy the mail-order and diabetes activities of German pharmaceutical company Apotal Group for an undisclosed sum.

Based on certain growth and profitability targets being achieved, the transaction will represent a multiple of 0.4x the target’s budgeted revenues for 2020.

The deal will be financed through available cash and up to 60.0 per cent of the purchase price will be funded via the issuing of new shares.

Subject to the green light from the German Federal Cartel Office, the acquisition is slated to complete during the third quarter of 2020.

Formed in 1980, Apotal is billed as one of the leading pharmacy brands in the country.

Its pharmacy operates e-commerce activities for over-the-counter medication, beauty and health products, as well as prescription drugs.

Apotal focuses mainly on diabetes patients and provides a range of offerings and services to help treat the disease.

In 2019, the group posted revenue of EUR 157.00 million, up 8.3 per cent from EUR 145 million in 2018.

Upon closing, 1.10 million of Apotal’s customers will join the buyer.

As a result of the acquisition, Zur Rose will serve more than 8.00 billion clients and strengthen its position as a market leader within the European market.

The target’s founder, Heinz-Peter Fichter, will continue to hold an operational position in the acquired activities and will become the managing director of Apotal’s diabetes division.

Zur Rose claims to be the largest e-commerce pharmacy in Europe, as well one of the leading medical wholesalers in Switzerland.

The company sells a range of health, beauty and personal care products through its brands DocMorris, eurapon, Blue Care and DoctiPharma, among others.

During the financial year ended 31st March 2010, Zur Rose posted revenue of EUR 426.56 million, up EUR 382.33 million from the corresponding period in 2019.

© Zephus Ltd